Delve into Vironexis' launch with a pipeline of 10 cancer drug candidates built around its AAV vectors platform.

Immunosuppressants used in adeno-associated virus (AAV) gene therapy for monogenic disorders present an adverse effect ...

A new study describes the use of artificial intelligence (AI) in designing a new generation of capsids, the structures that ...

The TRIM21 therapies have been shown to remove toxic tau proteins and reduce symptoms of neurodegeneration in mice.

Scientists from Spirovant Sciences describe SP-101, a novel adeno-associated virus (AAV) gene therapy for the treatment of ...

AAVantgarde Bio (AAVantgarde), an Italy-based global biotechnology company, announced that the first subject has been dosed in the LUCE-1 trial, a Phase 1/2 open label clinical trial to assess safety ...

AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today ...

Global AAV Contract Development and Manufacturing Organizations Market is valued at approximately USD 621 million in 2023 and is anticipated to grow with a healthy growth rate of more than 4.85 % over ...

Research successes are driving gene therapy for inherited deafness to the clinic, but commercialization efforts are needed to ...

Scientists from Spirovant Sciences describe SP-101, a novel adeno-associated virus (AAV) gene therapy for the treatment of cystic fibrosis (CF) in the peer-reviewed journal Human Gene Therapy.